LIFEVANTAGE CORP Selling and Marketing Expense
LIFEVANTAGE CORP (LFVN) reported Selling and Marketing Expense of $32.48 million for the 3-month period ending 2014-03-31, per its 10-Q filed 2014-05-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2014-05-06
- LIFEVANTAGE CORP selling and marketing expense for the quarter ending 2014-03-31 was $32.48M, a 8.84% increase year-over-year.
- LIFEVANTAGE CORP selling and marketing expense for the quarter ending 2013-12-31 was $29.79M, a 0.65% increase year-over-year.
- LIFEVANTAGE CORP selling and marketing expense for the quarter ending 2013-09-30 was $30.24M, a 2.38% increase year-over-year.
- LIFEVANTAGE CORP selling and marketing expense for the quarter ending 2013-06-30 was $33.41M, a 37.50% increase year-over-year.
- LIFEVANTAGE CORP selling and marketing expense for fiscal 2013 was $122.39M, a 78.94% increase from fiscal 2012.
- LIFEVANTAGE CORP selling and marketing expense for fiscal 2012 was $68.40M, a 224.77% increase from fiscal 2011.
- LIFEVANTAGE CORP selling and marketing expense for fiscal 2011 was $21.06M.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 3 month as first filed | Selling and Marketing Expense 6 month | Selling and Marketing Expense 6 month as first filed | Selling and Marketing Expense 9 month | Selling and Marketing Expense 9 month as first filed | Selling and Marketing Expense 12 month | Selling and Marketing Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2014-03-31 | $32.48M 10-Q · filed 2014-05-06 | $62.27M derived: sum of 2 quarters · filed 2014-05-06 | $92.51M 10-Q · filed 2014-05-06 | $125.92M derived: sum of 4 quarters · filed 2014-05-06 | ||||
| 2013-12-31 | $29.79M 10-Q · filed 2014-02-06 | $60.03M 10-Q · filed 2014-02-06 | $93.44M derived: sum of 3 quarters · filed 2014-02-06 | $123.28M derived: sum of 4 quarters · filed 2014-05-06 | ||||
| 2013-09-30 | $30.24M 10-Q · filed 2013-11-07 | $63.66M derived: sum of 2 quarters · filed 2013-11-07 | $93.50M derived: sum of 3 quarters · filed 2014-05-06 | $123.09M derived: sum of 4 quarters · filed 2014-05-06 | ||||
| 2013-06-30 | $33.41M derived: 10-K 12 month − 10-Q 9 month · filed 2013-09-12 | $63.26M derived: sum of 2 quarters · filed 2014-05-06 | $92.85M derived: sum of 3 quarters · filed 2014-05-06 | $122.39M 10-K · filed 2013-09-12 | ||||
| 2013-03-31 | $29.84M 10-Q · filed 2014-05-06 | $59.44M derived: sum of 2 quarters · filed 2014-05-06 | $88.98M 10-Q · filed 2014-05-06 | $113.28M derived: sum of 4 quarters · filed 2014-05-06 | ||||
| 2012-12-31 | $29.59M 10-Q · filed 2014-02-06 | $59.13M 10-Q · filed 2014-02-06 | $83.43M derived: sum of 3 quarters · filed 2014-02-06 | $103.11M derived: sum of 4 quarters · filed 2014-02-06 | ||||
| 2012-09-30 | $29.54M 10-Q · filed 2013-11-07 | $53.84M derived: sum of 2 quarters · filed 2013-11-07 | $73.52M derived: sum of 3 quarters · filed 2013-11-07 | $87.39M derived: sum of 4 quarters · filed 2013-11-07 | ||||
| 2012-06-30 | $24.30M derived: 10-K 12 month − 10-Q 9 month · filed 2013-09-12 | $43.98M derived: sum of 2 quarters · filed 2013-09-12 | $57.85M derived: sum of 3 quarters · filed 2013-09-12 | $68.40M 10-K · filed 2013-09-12 | $68.40M 10-K · filed 2012-09-10 | |||
| 2012-03-31 | $19.68M 10-Q · filed 2013-05-09 | $19.68M 10-Q · filed 2012-05-15 | $33.55M derived: sum of 2 quarters · filed 2013-05-09 | $44.10M 10-Q · filed 2013-05-09 | $44.10M 10-Q · filed 2012-05-15 | $52.38M derived: sum of 4 quarters · filed 2013-09-12 | ||
| 2011-12-31 | $13.88M 10-Q · filed 2013-02-07 | $13.88M 10-Q · filed 2012-02-14 | $24.42M 10-Q · filed 2013-02-07 | $24.42M 10-Q · filed 2012-02-14 | $32.70M derived: sum of 3 quarters · filed 2013-09-12 | $38.05M derived: sum of 4 quarters · filed 2013-09-12 | ||
| 2011-09-30 | $10.54M 10-Q · filed 2012-11-08 | $10.54M 10-Q · filed 2011-11-14 | $18.82M derived: sum of 2 quarters · filed 2013-09-12 | $24.17M derived: sum of 3 quarters · filed 2013-09-12 | $28.19M derived: sum of 4 quarters · filed 2013-09-12 | |||
| 2011-06-30 | $8.28M derived: 10-K 12 month − 10-Q 9 month · filed 2013-09-12 | $13.63M derived: sum of 2 quarters · filed 2013-09-12 | $17.65M derived: sum of 3 quarters · filed 2013-09-12 | $21.06M 10-K · filed 2013-09-12 | $21.06M 10-K · filed 2012-09-10 | |||
| 2011-03-31 | $5.35M 10-Q · filed 2012-05-15 | $9.37M derived: sum of 2 quarters · filed 2012-05-15 | $12.78M 10-Q · filed 2012-05-15 | |||||
| 2010-12-31 | $4.02M 10-Q · filed 2012-02-14 | $7.43M 10-Q · filed 2012-02-14 | ||||||
| 2010-09-30 | $3.41M 10-Q · filed 2011-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |